1. Background
2. Objectives
3. Methods
3.1. Isolation and Identification of MRSA Strains
3.2. Determination of Antibiotic Susceptibility Profiles
3.3. Phene-Plate Typing
3.4. DNA Extraction
3.5. Determination of SCCmec and ccr Types
3.6. Detection of Panton-Valentine Leukocidin (pvl) Gene
4. Results
4.1. Identification of Strains
| Sample | Intensive Care Unit | Surgery | Gynecology | Internal | Infectious Diseases | No. (%) |
|---|---|---|---|---|---|---|
| Male | 10 (21) | 19 (40) | - | 6 (13) | 12 (26) | 47 (64) |
| Female | 5 (19) | 8 (31) | 2 (8) | 4 (15) | 7 (27) | 26 (36) |
| Total | 15 (20) | 27 (37) | 2 (3) | 10 (14) | 19 (26) | 73 |
a Values are expressed as No. (%).
4.2. Antibiotic Susceptibility of MRSA Strains
| Pattern | Antibiotics | No. (%) of Strains | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD | TN | T | NI | K | AK | E | CIP | TS | RP | PG | GM | MN | ||
| 1 | + | 10 (14) | ||||||||||||
| 2 | + | + | + | + | + | + | + | + | 1 (1.4) | |||||
| 3 | + | + | + | + | + | + | + | + | + | 1 (1.4) | ||||
| 4 | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | |||
| 5 | + | + | + | + | + | + | + | + | + | 4 (5.5) | ||||
| 6 | + | + | + | + | + | + | 1 (1.4) | |||||||
| 7 | + | + | + | + | + | + | + | 1 (1.4) | ||||||
| 8 | + | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | ||
| 9 | + | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | ||
| 10 | + | + | + | + | + | + | + | + | + | + | + | + | 2 (2.8) | |
| 11 | + | + | + | + | + | + | + | + | + | + | + | 6 (8.2) | ||
| 12 | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | |||
| 13 | + | + | + | + | + | + | + | + | + | + | + | 3 (4.1) | ||
| 14 | + | + | + | + | + | + | + | + | + | + | + | 7 (9.6) | ||
| 15 | + | + | + | + | + | + | + | + | + | + | 2 (2.8) | |||
| 16 | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | |||
| 17 | + | + | + | + | + | + | + | + | + | + | 6 (8.2) | |||
| 18 | + | + | + | + | + | + | + | + | + | + | 5 (6.8) | |||
| 19 | + | + | + | + | + | + | + | + | + | + | + | 3 (4.1) | ||
| 20 | + | + | + | + | + | + | + | + | 1 (1.4) | |||||
| 21 | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | |||
| 22 | + | + | + | + | + | + | + | + | + | + | 1 (1.4) | |||
| 23 | + | + | + | + | + | + | + | + | + | + | 2 (2.8) | |||
| 24 | + | + | + | + | + | + | + | + | + | 1 (1.4) | ||||
| 25 | + | + | + | + | + | + | + | + | + | 2 (2.8) | ||||
| 26 | + | + | + | + | + | + | + | + | 5 (6.8) | |||||
| 27 | + | + | + | + | + | + | + | 1 (1.4) | ||||||
| 28 | + | + | + | + | + | + | + | + | 1 (1.4) | |||||
| 29 | + | + | + | + | + | + | 1 (1.4) | |||||||
Abbreviations: CD, clindamycin; TN, tobramycin; T, tetracycline; NI, nitrofurantoin; K, kanamycin; AK, amikacin; E, erythromycin; CIP, ciprofloxacin; TS, trimethoprim-sulfamethoxazole; RP, rifampicin; PG, penicillin G; GM, gentamicin; MN, minocycline.
| No | Gender | Ward | Year | PhP Type | Antibiotic Pattern | MIC OXA, µg/mL | MIC VAN, µg/mL | SCCmec Type | ccr Type | pvl | MRSA |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | ICU | 2019 | CT1 | 18 | 256 | 2 | III | 3 | - | HA- |
| 2 | Male | ICU | 2019 | CT1 | 4 | 96 | 1 | III | 3 | - | HA- |
| 3 | Female | Gynecology | 2019 | CT1 | 14 | 256 | 1 | III | 3 | - | HA- |
| 4 | Female | Infectious | 2019 | CT1 | 29 | 96 | 0.5 | III | 3 | - | HA- |
| 5 | Male | Surgery | 2019 | CT2 | 27 | 128 | 1 | III | 3 | - | HA |
| 6 | Male | Surgery | 2019 | ST1 | 20 | 256 | 0.25 | III | 3 | - | HA- |
| 7 | Female | Infectious | 2019 | CT3 | 14 | 256 | 2 | III | 3 | - | HA- |
| 8 | Male | ICU | 2019 | ST2 | 1 | 4 | 2 | IVa | 2 | + | CA- |
| 9 | Male | Gynecology | 2019 | CT2 | 17 | 96 | 1 | III | 3 | - | HA- |
| 10 | Female | Internal | 2019 | CT3 | 15 | 128 | 1 | III | 3 | - | HA- |
| 11 | Female | ICU | 2019 | CT2 | 17 | 256 | 0.5 | III | 3 | - | HA- |
| 12 | Female | Surgery | 2019 | CT2 | 22 | 256 | 0.5 | III | 3 | - | HA- |
| 13 | Male | ICU | 2019 | CT4 | 11 | 64 | 0.25 | III | 3 | - | HA- |
| 14 | Male | Internal | 2019 | CT2 | 23 | 256 | 0.125 | III | 3 | - | HA- |
| 15 | Male | Surgery | 2019 | CT2 | 28 | 256 | 0.25 | III | 3 | - | HA- |
| 16 | Female | Infectious | 2019 | CT2 | 24 | 64 | 0.125 | III | 3 | - | HA- |
| 17 | Male | Surgery | 2019 | CT3 | 12 | 256 | 0.5 | III | 3 | - | HA- |
| 18 | Female | Internal | 2019 | CT3 | 14 | 256 | 0.125 | III | 3 | - | HA- |
| 19 | Male | Infectious | 2019 | CT3 | 11 | 128 | 0.25 | III | 3 | - | HA- |
| 20 | Male | Surgery | 2019 | CT3 | 16 | 256 | 0.125 | III | 3 | - | HA- |
| 21 | Female | ICU | 2019 | ST3 | 1 | 4 | 0.5 | IVa | 2 | + | CA- |
| 22 | Male | ICU | 2019 | CT2 | 6 | 256 | 2 | III | 3 | - | HA- |
| 23 | Male | Surgery | 2019 | CT4 | 5 | 96 | 0.125 | III | 3 | - | HA- |
| 24 | Male | Surgery | 2019 | CT2 | 18 | 128 | 2 | III | 3 | - | HA- |
| 25 | Male | ICU | 2019 | ST4 | 1 | 8 | 0.125 | V | 5 | + | CA- |
| 26 | Male | Infectious | 2019 | ST5 | 1 | 4 | 0.5 | IVc | 2 | + | CA- |
| 27 | Female | Infectious | 2019 | ST6 | 1 | 6 | 1 | V | 5 | + | CA- |
| 28 | Female | Surgery | 2019 | CT2 | 26 | 256 | 1 | III | 3 | - | HA- |
| 29 | Female | Infectious | 2019 | CT4 | 1 | 8 | 2 | IVa | 2 | + | HA- |
| 30 | Male | Internal | 2019 | CT2 | 17 | 128 | 1 | III | 3 | - | HA- |
| 31 | Female | Surgery | 2019 | ST7 | 7 | 96 | 2 | III | 3 | - | HA- |
| 32 | Male | Surgery | 2019 | CT2 | 25 | 256 | 0.5 | III | 3 | - | HA- |
| 33 | Female | Infectious | 2019 | CT5 | 1 | 6 | 0.5 | IVa | 2 | + | HA- |
| 34 | Female | ICU | 2019 | CT2 | 23 | 256 | 1 | III | 3 | - | HA- |
| 35 | Male | Infectious | 2019 | CT2 | 26 | 256 | 0.5 | III | 3 | - | HA- |
| 36 | Male | Infectious | 2020 | CT2 | 25 | 64 | 0.5 | III | 3 | - | HA- |
| 37 | Female | Surgery | 2020 | CT2 | 26 | 96 | 1 | III | 3 | - | HA- |
| 38 | Male | Surgery | 2020 | CT3 | 14 | 256 | 0.125 | III | 3 | - | HA- |
| 39 | Male | ICU | 2020 | CT3 | 3 | 128 | 1 | III | 3 | - | HA- |
| 40 | Male | Surgery | 2020 | ST8 | 10 | 256 | 1 | III | 3 | - | HA- |
| 41 | Male | Infectious | 2020 | CT2 | 18 | 96 | 0.5 | III | 3 | - | HA- |
| 42 | Female | Surgery | 2020 | CT3 | 5 | 96 | 0.125 | III | 3 | - | HA- |
| 43 | Male | Infectious | 2020 | CT6 | 19 | 256 | 0.5 | III | 3 | - | HA- |
| 44 | Male | Surgery | 2020 | CT6 | 11 | 256 | 0.25 | III | 3 | - | HA- |
| 45 | Male | ICU | 2020 | CT3 | 14 | 256 | 0.125 | III | 3 | - | HA- |
| 46 | Male | Internal | 2020 | CT2 | 19 | 128 | 0.25 | III | 3 | - | HA- |
| 47 | Male | Infectious | 2020 | CT2 | 26 | 128 | 0.125 | III | 3 | - | HA- |
| 48 | Female | Infectious | 2020 | CT3 | 13 | 256 | 0.25 | III | 3 | - | HA- |
| 49 | Male | ICU | 2020 | CT2 | 10 | 96 | 0.25 | III | 3 | - | HA- |
| 50 | Male | Internal | 2020 | CT5 | 14 | 128 | 1 | III | 3 | - | HA- |
| 51 | Male | Surgery | 2020 | CT7 | 18 | 256 | 0.25 | III | 3 | - | HA- |
| 52 | Male | Infectious | 2020 | CT2 | 21 | 256 | 0.25 | III | 3 | - | HA- |
| 53 | Male | Surgery | 2020 | CT2 | 8 | 256 | 0.25 | III | 3 | - | HA- |
| 54 | Male | Surgery | 2020 | CT4 | 14 | 256 | 0.25 | III | 3 | - | HA- |
| 55 | Female | ICU | 2020 | CT7 | 13 | 256 | 0.25 | III | 3 | - | HA- |
| 56 | Female | Surgery | 2020 | ST9 | 1 | 8 | 0.25 | IVa | 2 | + | CA- |
| 57 | Male | Internal | 2020 | ST10 | 1 | 16 | 0.25 | V | 5 | + | CA- |
| 58 | Male | Surgery | 2020 | CT2 | 13 | 128 | 0.125 | III | 3 | - | HA- |
| 59 | Male | Infectious | 2020 | CT3 | 1 | 4 | 0.25 | IVc | 2 | + | CA- |
| 60 | Female | Surgery | 2020 | CT2 | 18 | 256 | 1 | III | 3 | - | HA- |
| 61 | Female | Infectious | 2020 | CT2 | 26 | 256 | 1 | III | 3 | - | HA- |
| 62 | Male | Surgery | 2020 | CT2 | 17 | 128 | 0.125 | III | 3 | - | HA- |
| 63 | Female | ICU | 2020 | ST11 | 15 | 256 | 2 | III | 3 | - | HA- |
| 64 | Male | Infectious | 2020 | CT2 | 17 | 128 | 0.125 | III | 3 | - | HA- |
| 65 | Male | Infectious | 2020 | CT8 | 5 | 256 | 2 | III | 3 | - | HA- |
| 66 | Male | Surgery | 2020 | CT5 | 11 | 256 | 0.25 | III | 3 | - | HA- |
| 67 | Female | Internal | 2020 | CT8 | 11 | 96 | 0.5 | III | 3 | - | HA- |
| 68 | Female | Internal | 2020 | CT8 | 5 | 256 | 1 | III | 3 | - | HA- |
| 69 | Male | ICU | 2020 | CT2 | 2 | 256 | 2 | III | 3 | - | HA- |
| 70 | Male | Internal | 2020 | CT2 | 17 | 128 | 0.25 | III | 3 | - | HA- |
| 71 | Female | Surgery | 2020 | CT4 | 11 | 256 | 2 | III | 3 | - | HA- |
| 72 | Male | Surgery | 2020 | CT2 | 9 | 256 | 2 | III | 3 | - | HA- |
| 73 | Male | Surgery | 2020 | CT2 | 19 | 128 | 2 | III | 3 | - | HA- |
Abbreviations: OXA, oxacillin; VAN, vancomycin; CA, community acquired; HA, hospital-acquired.
